Should we encourage over-the-counter statins? A population perspective for coronary heart disease prevention

American Journal of Cardiovascular Drugs

Volumn 7, Issue 4, 2007, Pages 299-302

  Gemmell, Islay ^a   Verma, Arpana ^a   Harrison, Roger A ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Bolton Primary Care Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NON PRESCRIPTION DRUG;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; FOOD AND DRUG ADMINISTRATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES;

ADULT; CORONARY DISEASE; DRUGS, NON-PRESCRIPTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; POPULATION SURVEILLANCE; UNITED STATES;

EID: 34548075247     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707040-00007     Document Type: Article

References (25)

1. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326 (7404): 1423-7
2. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279 (20): 1615-22
3. Shepherd J. Who should receive a statin these days? Lessons from recent clinical trials. J Intern Med 2006; 260 (4): 305-19
4. Joint Meeting of the Nonprescription Drugs Advisory Committee and the Endocrinologic and Metabolic Drugs Advisory Committee [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4086M1.htm [Accessed 2006 Oct 20]
5. Dyer O. Consumers' Association voices concern at over the counter statins. BMJ 2004; 329 (7461): 310-e
6. Heller RF, Dobson AJ. Disease impact number and population impact number: population perspectives to measures of risk and benefit. BMJ 2000; 321 (7266): 950-2
7. Heller RF, Edwards R, Mcelduff P. Implementing guidelines in primary care: can population impact measures help? BMC Public Health 2003; 3: 7
8. Heller RF, Page J. A population perspective to evidence based medicine: 'evidence for population health'. J Epidemiol Community Health 2002; 56 (1): 45-7
9. Ford ES, Giles WH, Mokdad AH. The distribution of 10-year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. J Am Coll Cardiol 2004; 43 (10): 1791-6
10. National Institutes of Health. Third report of the National cholesterol Education Program Expert Pannel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Washington, DC: National Institutes of Health, 2001. Report no: 01-3670
11. Wilsom PW, D'Agostimo RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47
12. Ketola E, Sipila R, Makela M. Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors. Ann Med 2000; 32 (4): 239-51
13. Gotto AM. Over-the-counter statins are worth considering in primary prevention of cardiovascular disease. Circulation 2006; 114 (12): 1310-4
14. LaFleur J, Thompson CJ, Joish VN, et al. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. Ann Pharmacother 2006; 40 (7-8): 1274-9
15. Eriksson KM, Westborg CJ, Eliasson MCE. A randomized trial of lifestyle intervention in primary healthcare for the modification of cardiovascular risk factors: the Bjorknas study. Scand J Public Health 2006; 34 (5): 453-61
16. Brass EP. Consumer behavior in the setting of over-the-counter statin availability: lessons from the consumer use study of OTC Mevacor. Am J Cardiol 2004; 94 (9): 22F-9F
17. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998; 279 (18): 1458-62
18. Population projections: United States by state, age and sex, for the years 2004-2030 [online]. Available from URL: URL:http://wonder.cdc.gov/WONDER/ help/PopulationProjections.HTML [Accessed 2006 Nov 21]
19. Gotto AM. Over-the-counter statins and cardiovascular disease prevention: perspectives, challenges, and opportunities. Clin Pharmacol Ther 2005; 78 (3): 213-7
20. Sever P, Dahlöf B, Poulter N, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361 (9364): 1149-58
21. Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circ J 2004; 68: 860-7
22. Silva MA, Swanson AC, Gandhi PJ, et al. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28 (1): 26-35
23. Barter PJ, Rye KA. The argument against the appropriateness of over-the-counter statins. Circulation 2006; 114 (12): 1315-20
24. Hughes S. Over the counter statins. J Cardivasc Nurs 2004; 19 (6): 430-1
25. Abrams J. Over-the-counter statins: a new controversy. Nat Clin Pract Cardiovasc Med 2005; 2 (4): 174-5